Try our beta test site
35 studies found for:    Northwestern AND Multiple sclerosis
Show Display Options
Rank Status Study
1 Recruiting Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study
Condition: Multiple Sclerosis
Interventions: Procedure: Hematopoietic Stem Cell Therapy;   Drug: Standard treatment with a conventional drug
2 Withdrawn Continuous Positive Airway Pressure (CPAP) for Fatigue in Patients With Multiple Sclerosis (MS) and Obstructive Sleep Apnea (OSA)
Conditions: Fatigue;   Multiple Sclerosis;   Sleep Apnea
Interventions: Device: Auto-titration CPAP;   Device: Sham-CPAP
3 Completed
Has Results
Stress Management for Patients With Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Behavioral: Individual Stress Management;   Other: Wait List Control
4 Terminated
Has Results
Hematopoietic Stem Cell Therapy for Patients With Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Biological: Hematopoietic stem cell transplantation
5 Completed Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Autologous Peripheral Blood Stem Cell or Bone Marrow Rescue in Patients With Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: cyclophosphamide;   Drug: filgrastim;   Drug: methylprednisolone;   Procedure: Autologous Stem Cell Transplantation
6 Unknown  A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Other: MSDX Complex-1 Biomarker test
7 Unknown  A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Other: MSDx Complex-1 Biomarker Test
8 Recruiting Stem Cell Transplantation for Stiff Person Syndrome (SPS)
Condition: Stiff Person Syndrome
Intervention: Biological: Autologous Hematopoietic Stem Cell Transplantation
9 Completed Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Procedure: Stem Cell Transplanataion
10 Completed
Has Results
Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Dalfampridine-ER 5mg;   Drug: Dalfampridine-ER 10mg;   Other: Placebo
11 Completed
Has Results
Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: Interferon beta 1-a;   Drug: glatiramer acetate;   Other: placebo
12 Active, not recruiting Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
Conditions: Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Secondary Progressive
Interventions: Drug: ibudilast;   Drug: Placebo
13 Completed Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Natalizumab;   Drug: Placebo
14 Recruiting Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Condition: Multiple Sclerosis
Interventions: Drug: MD1003 100mg capsule;   Drug: PLACEBO
15 Completed
Has Results
Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Fingolimod;   Drug: Placebo
16 Completed A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention:
17 Completed Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
Conditions: Autoimmune Diseases of the Nervous System;   Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Disease Progression;   Brain Atrophy
Interventions: Biological: Tcelna;   Biological: Placebo
18 Completed IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: IPX056 20 mg;   Drug: IPX056 40 mg;   Drug: Encapsulated Baclofen 20 mg;   Drug: Placebo Baclofen Tablet;   Drug: IPX056 10 mg;   Drug: IPX056 30 mg;   Drug: IPX056 35 mg;   Drug: Placebo IPX056 20 mg;   Drug: Placebo IPX056 40 mg
19 Completed
Has Results
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: Alemtuzumab;   Biological: Interferon beta-1a
20 Completed
Has Results
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: Alemtuzumab 12 mg;   Biological: Alemtuzumab 24 mg;   Biological: Interferon beta-1a

   Previous Page Studies Shown (1-20) Next Page (21-35) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.